A Single Dose Pharmacokinetic Study of ray1225 in Subjects With Varying Degrees of Hepatic Impairment

Participants with an allergic disposition (multiple drug and food allergies) or who, as determined by the investigator, are likely to be allergic to the investigational drug product or any component of the investigational drug product;

QTcF> 450ms;

Participants with serious infections, trauma, gastrointestinal surgery or other major surgical procedures within 4 weeks;

Participates who donated blood or bleeding profusely (> 400 mL) in the 3 months;

Pregnant or lactating women, or women of childbearing age with a positive pregnancy test;

Smoking averaged more than 10 cigarettes per day in the 3 months prior to screening;

Have a personal or family history of medullary thyroid carcinoma or have multiple endocrine neoplasia syndrome type 2;

Participants with Normal Hepatic Function Only:

Any history of hepatic impairment, or potential presence of liver function impairment by physical examination and laboratory examination at screening.

Participants with Hepatic Impairment Only:

Any history of clinically serious illness or disease or condition except for primary liver disease that the investigator believes may affect the results of the trial, including but not limited to a history of circulatory, endocrine, nervous, digestive, urinary, respiratory or hematological, immune, psychiatric, and metabolic disorders.

Participants with drug-induced liver injury; history of liver transplantation; cirrhosis in combination with the following complications: including but not limited to liver failure, hepatic encephalopathy, hepatocellular carcinoma, esophageal bleeding from ruptured fundic varices.